Pressrum

Nyheter och pressmeddelanden

Här kan du läsa nyheter och pressmeddelanden om Paindrainer. Vi lägger även ut lediga tjänster, så håll ögonen öppna!

No items found.
11/18/2026

Paindrainer AB Renews SOC 2 Type 2 Attestation, Reinforcing Its Commitment to Data Security and Trust

LUND, SWEDEN – Paindrainer AB is proud to announce that the company now has successfully renewed its SOC 2 Type 2 attestation for its medical device, PD Care System, following a thorough external audit process. This milestone underscores Paindrainer’s continued commitment to protecting partner and patient data by meeting the highest standards of data security in digital health.

Läs mer
Read more
No items found.
11/16/2026

Paindrainer AB presented as one of the awards nominees for the prestigious Prix Galien Bridges 2026

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, is proud to be selected as one of the awards nominees for the esteemed Prix Galien Bridges 2026 awards. Paindrainer has been selected as a nominee in the category for best medical technology. The outcome will be presented on dec 1st 2026 at the Prix Galien gala in Stockholm.

Läs mer
Read more
No items found.
10/28/2026

A collaborative clinical trial validates Paindrainer´s digital device and presents the first neurophysiological biomarker in digital pain management

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces the publication of a clinical trial, conducted in a collaboration between Lund University and Cleveland Clinic, in Nature´s Scientific Reports. The study shows that standard of care complemented with Paindrainer´s digital tool resulted in significant improvements in pain intensity, physical function and pain interference in patients with chronic pain. Importantly, a longitudinal increase in EEG gamma power was shown to accompany the reduction in pain score, representing a novel neurophysiological biomarker for digital management of chronic pain.

Läs mer
Read more
No items found.
9/10/2026

Paindrainer AB expands its U.S. footprint through a commercial collaboration with Chronic Care LLC

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces that the company has signed a partnership agreement for its unique Remote Therapeutic Monitoring solution with Chronic Care LLC that will enable access to new Pain Management clinics in the US.

Läs mer
Read more
No items found.
5/14/2026

The health-economic study presents improved healthcare, productivity and quality of life when using Paindrainer´s AI-powered digital tool for self-management of persistent pain

MEDICON VILLAGE, LUND, SWEDEN – A health-economic study of an AI-powered digital tool, designed by Paindrainer AB (Lund) for self-management of persistent pain, has been accepted after peer review and published in Pain Medicine, the official journal of the American Academy of Pain Medicine. The study was conducted by researchers at the Swedish Institute for Health Economics (IHE), Lund University, Tufts University School of Medicine and Newton-Wellesley Hospital, and Weill Cornell Medicine.

Läs mer
Read more
No items found.
5/12/2026

Paindrainer AB raises 6 million in a Q2 2026 share issue process

LUND, SWEDEN – Paindrainer AB announces a successfully completed share issue of 6.0 MSEK, supported by shareholder Almi Invest and Tramontane Invest as corner investors alongside a committed group of existing and new shareholders.

Läs mer
Read more
No items found.
4/9/2026

Paindrainer AB Launch Relivra, the first voice controlled, agentic AI powered app to Support Individuals Living with Persistent Pain

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB today announces the launch of Relivra, a unique AI-powered digital companion designed to support individuals living with persistent pain. The product offers a self-paced, interactive learning experience built on established behavioural scientific and clinical principles.

Läs mer
Read more
No items found.
12/22/2025

Paindrainer AB to be granted Japanese patent for its unique patient-centric concept for chronic pain management

LUND, SWEDEN – Paindrainer AB, a leading innovator in digital healthcare, announces that the Japanese Patent Office has confirmed patentability of the company’s proprietary artificial-neural-network-driven platform for comprehensive, patient-centric chronic pain management.

Läs mer
Read more
Kom igång

Ladda ner appen och börja idag!

Vill du förstå hur dina aktiviteter påverkar smärtnivån och förbättra din livskvalitet? Du får 14 dagar provperiod. 100% av deltagarna i den kliniska studien på Weill Cornell Medicine i New York angav bättre förståelse hur deras aktiviteter påverkar deras smärtnivå.

Screenshot från appens första sida.